Atrial fibrillation in essential hypertension

Abstract

Many clinical studies indicate that atrial fibrillation is closely related to hypertension. Atrial fibrillation is not only associated with the level of blood pressure (BP) but also with the circadian rhythms of BP. However, the underlying mechanisms of atrial fibrillation in essential hypertension patients remain largely unknown. Hypertension may facilitate the onset and persistence of atrial fibrillation by stretch-induced changes in the repolarization of atrial myocytes (triggers of atrial fibrillation) and atrial remodeling (structural and electrical remodeling). Importantly, the effects of hypertension on atrial fibrillation are progressive. These progressive anatomic, functional, electrophysiological and structural changes occur at different times. This characterization of the time course of atrial changes presents an intervention window before remodeling progresses to changes that are difficult to reverse. Given that the medium to long-term efficacy of antiarrhythmic drugs has proved poor, it is essential to seek new therapies to prevent the onset of atrial fibrillation and to effectively control recurrences of atrial fibrillation. The study of nonantiarrhythmic drugs that act on the atrial remodeling that constitutes the substrate of the arrhythmia is a new and very interesting field of research. Treatment with angiotensin-converting enzyme inhibitors angiotension-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) seems more promising. However, from recent trials, only hypertension with structural heart disease, left ventricular dysfunction and left ventricular hypertrophy benefit from ACEIs and ARBs. This article reviews many aspects of atrial fibrillatio in essential hypertension patients to provide the foundation of atrial fibrillatio treatment.

Obesity and atrial fibrillation: A comprehensive review of the pathophysiological mechanisms and links

“…The wavelength is a product of refractory period and conduction velocity (WL = CV Â RP). The shortening of refractoriness, in combination with a decrease in conduction velocity, results in a shorter atrial wavelength, thus favoring reentry [39]. In an experimental model, hypertension increased AF inducibility through a decrease in I CaL and an increase in atrial fibrosis [40].…”

Biomarkers of Inflammation, Thrombogenesis, and Collagen Turnover in Patients With Atrial Fibrillation

“…2 The rising prevalence of AF is not solely attributed to the increasing elderly population but also to the increasing number of individuals with high body mass index, diabetes mellitus, hypertension, and other known risk factors for AF. 3,4 Atrial fibrillation is associated with significant morbidity and mortality due to the increases in adverse events, such as stroke, systematic embolism, and heart failure. The exact underlying pathophysiology of AF remains largely unknown.…”

Impact of GGCX polymorphisms on warfarin doserequirements in atrial fibrillation patients

“…The incidence of AF is 1%-2% in the general population and it is increased with age, heart failure, and hypertension (2)(3)(4). AF patients have increased risk of complications, such as strokes and systemic thromboembolism (5), which can be reduced by anticoagulant therapy such as warfarin (6).…”